Home World News FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer World News FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 921 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 2026 ESMO Breast Cancer Award Recipient Announced March 31, 2026 7 Tips For Keeping The Entire Family Healthy During Flu Season October 17, 2019 Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... September 26, 2023 Load more HOT NEWS How to Make the Most of Your Patient Portal During Cancer Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... EMA Recommends Granting a Marketing Authorisation for Crisantaspase Καρκίνος οισοφάγου
